A partnership deal between the Dutch digital health company Congenica and clinical trial platform provider myTomorrows will see the companies pooling their technologies to help more patients receive precision oncology treatments.
Insilico Medicine is due to receive $80 million upfront plus potential milestone payments as Exelixis gains global rights to develop and commercialize the Hong Kong firm’s small molecule cancer treatment.
The AstraZeneca-owned company Alexion has teamed up with Verge Genomics to deploy the U.S. startup’s drug discovery platform in the search for novel drug targets for rare neurodegenerative and neuromuscular diseases.
The increasing prevalence of chronic diseases could see the market for active pharmaceutical ingredients (APIs) growing by 7.5% per year, says a report by Prophecy Market Insights.
An oral treatment, developed by the U.S. company Crinetics Pharmaceuticals, Inc., has shown promise as an alternative to injected therapies for tackling the rare disease acromegaly in a phase 3 trial.
OSP spoke to Vesta Marciulioniene, director global regulatory clinical services at ICON Biotech, a contract research organisation who shares insights on the new EMA guideline for computerised systems and electronic data in clinical trials and what new...
HumanFirst, a cloud-based software company accelerating patient-centered drug development through AI, has announced the launch of its precision measures platform.
Glasgow diagnostics spinout Microplate Dx has closed a £2.5 million seed funding round to develop its point-of-care diagnostic platform, which can confirm the presence of bacteria and rapidly identify effective antibiotics to use and which ones to avoid....
The U.S. company Nimbus Therapeutics has raised $210 million in a financing round to fund the development of small molecule drugs powered by computational drug discovery.
A benchtop DNA sequencer developed by the U.S. DNA sequencing company Element Biosciences, Inc., has seen sales grow by triple digits and has received more than 100 orders since its launch in March 2022.
The UK organ-on-a-chip (OOC) company CN Bio has teamed up with LifeNet Health LifeSciences to gain access to the non-profit tissue bank’s validated human cells for use in organ models for life sciences research.
CymaBay announced recently the initiation of its 52-week, placebo-controlled, randomized, phase 3 study — 'Intended to Determine the Effects of seladelpar on normalization of Alkaline phosphatase (ALP) Levels in subjects with Primary Biliary Cholangitis...
The UK startup Intelligent OMICS (Intellomx) has launched a collaboration with Johnson & Johnson’s pharmaceutical company Janssen to use artificial intelligence (AI) to discover drug targets for the treatment of blood cancer.
Less than a month after the U.S. Food and Drug Administration (FDA) gave its antidepressant drug zuranolone (Zurzuvae) a mixed welcome, Sage Therapeutics has launched plans to reorganize its operations by refocusing its drug development efforts and laying...
The small molecule drug alectinib (Alecensa) developed by the big pharma company Roche has improved disease-free survival in patients with a specific form of non-small cell lung cancer (NSCLC) when delivered as an adjuvant therapy in a phase 3 trial.
Andrew MacGarvey is chief operating officer (COO) of Phastar. We caught up with him earlier in the summer at DIA Global in Boston to discuss the company’s origins, opportunities for big analytical data DCTs, artificial intelligence and machine learning...
Eight new companies have joined The BioInnovation Institute’s (BII’s) Venture Lab acceleration program for early-stage companies, it was announced today (August 31).
More people are talking about mental illness than ever before. However, despite increased awareness, it remains one of the most neglected areas of public health globally, with research and quality of care lagging behind physical health conditions.
With more than 63 biopharma companies attending and 15 event partners sharing solutions, the 7th Annual IPF Summit being held in Boston next month (September 2023) is not to be missed.
Danaher is to acquire Abcam for $24 per share - a total enterprise value of approximately $5.7 billion representing approximately 40% more than Abcam's undisclosed share prices in May.
CDMO, Sirio Europe, is launching two new softgels aimed at those who want to develop in the pharmaceutical consumer health space at this year’s CPHI in Barcelona.
STARLIMS, a company that provides enterprise informatics solutions has acquired Labstep, a research and development (R&D) electronic laboratory notebook (ELN).
Emerald Cloud Lab (ECL) was the world’s first highly automated cloud laboratory, was set up by two friends, Brian Frezza and D.J Kleinbaum who grew up together and joined forces after their PhDs to found the company.
Mahana Therapeutics announced last week (August 22) that it was entering into a multi-million dollar distribution and marketing partnership with the consumer health division of Bayer.
FORE Biotherapeutics yesterday (August 23) announced the closing of its $75 million (£59 million) series D financing, led by the SR One and co-led by Medicxi and joined by existing investors.
A partnership between Banner Health and nference will offer more ‘potent insight generation, offering researchers the option to examine more inclusive data’.
With so many advanced therapies on the horizon, the next few years are poised to be one of significant progress for patients with over 2000 cell and gene therapies in active clinical trials globally.
QuantHealth announced it has raised a $15 million series A funding round today (August 22) for its clinical simulator that can predict how a patient will respond to treatment in a clinical trial.
Actimed Therapeutics Ltd will put some of its additional funding of £4.75 million ($6 million) towards its attempt to provide the world’s first cure for cancer cachexia.
Another company OSP was lucky enough to catch up with at DIA Global in Boston this year, was well-established generative artificial intelligence (AI) software company, Yseop.
The US Food and Drug Administration (FDA) has given orphan drug designation (ODD) to Redx’s Zelasudil for the potential treatment of idiopathic pulmonary fibrosis (IPF).
A kidney disease drug with a ‘durable and clinically meaningful impact on kidney function’ has been granted priority review by the US Food and Drug Administration (FDA).
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorizations for Pombliti + Opfolda, a two-component therapy to treat Pompe disease.
Integrated drug formulation and clinical trials company, BDD Pharma, will be expanding its phase appropriate development, manufacturing, and clinical testing services after a £2 million ($1.3 million) investment.
BioPharma Reporter and Outsourcing Pharma presents its latest round-up of the movers and shakers in the pharma industry. From Karuna Therapeutics to IO Biotech, we break down the key changes on the pharmaceutical job ladder.
Rohit Nambisam is CEO of Lokavant, OSP caught up with him at DIA Global in Boston earlier this summer to find out more about him and the work he is passionate about.
OSP discussed going beyond industry sponsors and how to support both patients and centers through clincal trial design with Erin Leckrone, senior director, clinical trials and Kathleen Kane, senior manager, clinical operations, at Be The Match BioTherapies....
The first patient has been dosed with an orally available small molecule cancer immunotherapy drug, Sosei Group Corporation and Cancer Research UK have announced.
Healthcare technology company Koneska is extending its contribution to critical neuroscience research by collaborating with an academic partnership program.
A partnership between technology company Fluree and Vitality TechNet is a ‘groundbreaking effort’ to shorten timelines within the drug discovery process.
Calliditas Therapeutics AB’s phase 3 study looking at a cure for a kidney disease called IgA nephropathy (IgAN) has met its primary endpoint and the full data has been published in The Lancet.
LighthouseAI, a company that specializes in compliance solutions for the pharmaceutical supply chain, has announced a $2.25 million seed round, led by Healthy Ventures with participation from Bertelsmann Next.
